Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,233 shares of the specialty pharmaceutical company’s stock after selling 939 shares during the period. Vontobel Holding Ltd.’s holdings in Jazz Pharmaceuticals were worth $521,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JAZZ. UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the last quarter. Ellsworth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after purchasing an additional 149 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Jazz Pharmaceuticals by 2.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock valued at $868,000 after buying an additional 155 shares during the last quarter. Cooper Financial Group raised its holdings in Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 156 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its position in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after buying an additional 165 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 5,053 shares of company stock worth $617,442 over the last ninety days. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $134.96 on Thursday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.16 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 1.02 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27. The stock’s 50-day simple moving average is $124.32 and its 200-day simple moving average is $117.68.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Robert W. Baird increased their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.